|Place of Origin:||China|
|Model Number:||0.5mg, 1.0mg|
|Minimum Order Quantity:||500, 000 capsules|
|Payment Terms:||L/C, T/T|
|Supply Ability:||One million pills per day|
|Product:||Sirolimus Capsules||Specification:||0.5mg, 1.0mg|
|Standard:||In - House||Packing:||10’s/blister|
Sirolimus Capsules 0.5mg, 1.0mg Oral Medications
Product : Sirolimus Capsules
Specification : 0.5mg, 1.0mg
Standard : In - house
Packing : 10’s/blister
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
For the prophylaxis of organ rejection in patients receiving renal transplants.
Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.
Mechanism of action
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.